Gensight Biologics News and Activities

Presence

GenSight Biologics develops gene therapies for neurodegenerative retinal diseases. Its products and services focus on eye disease treatment programs for patients, hospitals, and specialist healthcare providers.

Gensight Biologics products and services overview:

Gene therapy
Eye disease therapy
Retinal treatments
Clinical research

Revenue: ~$1 million

Employees: 60

Headquarters: Paris, France

Gensight Biologics is one of the...

Gensight Biologics is a company listed under the stock ticker SIGHT (FR).

Executives

View the org chart displaying its 19 main executives

Most searched biographies at Gensight Biologics

Popular executive movements at Gensight Biologics

Magali Gibou, Vice President, Regulatory and Quality, has left the company (posted on February 19 2026).
Fang Li has joined the company as Chief Regulatory Affairs & Quality Officer (posted on February 19 2026).
Sabrina Chekroun has joined the company as Senior Vice President, Regulatory Affairs and Quality (posted on February 19 2026).

Create your alert
to follow the executive moves at Gensight Biologics.